- Public display name
- Pfizer
- Canonical source name
- Pfizer Inc.
- Organization type
- Corporation
- Profile reporting period
- Q1–Q2 2026
No former-name evidence is used for this profile.
Organization profile
Pfizer
Pfizer Inc.'s reviewed disclosures support a focused profile of reported federal activity involving health, Medicare and Medicaid, pharmacy, tax, trade, and related policy areas.
Data retrieved through Sep 4, 2026; profile content reviewed Sep 5, 2026
Official identity and role
Reviewed identity and coverage
This profile includes only the exact reviewed Pfizer Inc. client alias; punctuation variants returned by the search remain outside the retained set.
Coverage summary
Count canonical filings after the reviewed exact-alias and amendment/duplicate rules; group each retained filing by its reported year and quarter.
- Period
- 2026 Q1 through 2026 Q2
- Canonical filings
- 8
- Source-record client names
- 1
- Registrant names
- 4
| Quarter | Filing count |
|---|---|
| 2026 Q1 | 4 |
| 2026 Q2 | 4 |
- Approved exact aliases
- PFIZER INC.
- Included source names
- PFIZER INC.
- Excluded candidate records
- 12
- Superseded records
- 0
Show 3 excluded source names
- PFIZER
- PFIZER, INC
- PFIZER, INC.
Period: 2026 Q1 through 2026 Q2 Reviewed 2026-09-04
Calculated from selected records
Reproducible observations
These concise statements come before the filing list so the scope and main record patterns are visible without opening every disclosure.
What the selected records show
- The current reviewed collection contains 8 canonical filings across 2 reporting quarters.
- 2026 Q1 contains 4 retained filings; 2026 Q2 contains 4 retained filings.
- Those filings preserve 1 distinct source-record client name and 4 distinct registrant names.
- The selected filings contain 9 official LDA issue codes; filing counts by code may overlap because one filing can report multiple codes.
- The outside-income reporting basis identifies 3 distinct outside registrant organizations in this period.
These observations are reproducible counts, not rankings or claims about importance, motive, access, effectiveness, or policy outcomes.
Lobbying disclosure
Lobbying disclosure
A lobbying disclosure reports activity under federal disclosure law. It does not show that the activity achieved a policy result.
Quarterly amounts, kept separate
Self-reported expenses and income reported by outside registrants have different reporting bases. They are displayed in separate tables and never added into one total.
| Reporting quarter | Measure | Value or state | Input states |
|---|---|---|---|
| 2026 Q1 | Self-reported expenses | $4,420,000 | 4 filings; 1 numeric; 3 other-measure; 0 unavailable |
| 2026 Q2 | Self-reported expenses | $1,880,000 | 4 filings; 1 numeric; 3 other-measure; 0 unavailable |
For each quarter, sum only retained filings' self-reported expense fields. A blank expense field is excluded from this series when the same filing establishes an outside-income reporting basis. Keep zero and every unavailable state visible; never add outside-registrant income. Reviewed 2026-09-04.
| Reporting quarter | Measure | Value or state | Input states |
|---|---|---|---|
| 2026 Q1 | Outside-registrant income | $270,000 | 4 filings; 3 numeric; 1 other-measure; 0 unavailable |
| 2026 Q2 | Outside-registrant income | $270,000 | 4 filings; 3 numeric; 1 other-measure; 0 unavailable |
For each quarter, sum only retained filings' outside-registrant income fields. A blank income field is excluded from this series when the same filing establishes a self-expense reporting basis. Keep zero and every unavailable state visible; never add self-reported expenses. Reviewed 2026-09-04.
Input LDA filings for coverage and amount calculations
- Lobbying disclosure
17640998-df82-47e3-8ad7-0afe51148524 - Lobbying disclosure
2cc79e15-9bc4-4964-8548-7e08d69a08b5 - Lobbying disclosure
58be6f34-3d49-47c5-b374-344da1198e80 - Lobbying disclosure
8f2443e8-3a53-4dc9-b865-a33dae4bc86e - Lobbying disclosure
9cdc8552-13e7-4a50-83eb-10376b07ab0e
Show 3 more source records
- Lobbying disclosure
dd2425d1-a5b8-44b3-8e63-c481f0bce531 - Lobbying disclosure
dd31025d-92a7-4fb3-87ab-b3fc6ae1d498 - Lobbying disclosure
fbad5885-a4be-4f7d-a3d3-41b2386ef55d
Issue categories in the filings
Health Issues, Pharmacy, Medicare/Medicaid, Taxation, Trade, Tariff, Labor, Budget, and intellectual-property codes remain separate in the table. The site does not collapse them into a single health-policy label.
Official issue-code distribution
Count every official LDA issue code present in the retained canonical filings. Count a filing once per code, preserve the official source label, and identify a normalized directory group only when the code is in that group's reviewed allowlist.
| Code and official label | Filings | Activities | Normalized directory group |
|---|---|---|---|
BUD — Budget/Appropriations | 2 | 2 | taxes government spending |
CPT — Copyright/Patent/Trademark | 2 | 2 | No current directory group |
HCR — Health Issues | 6 | 6 | healthcare drug policy medicare |
LBR — Labor Issues/Antitrust/Workplace | 2 | 2 | No current directory group |
MMM — Medicare/Medicaid | 4 | 4 | healthcare drug policy medicare |
PHA — Pharmacy | 2 | 2 | healthcare drug policy medicare |
TAR — Tariff (miscellaneous tariff bills) | 2 | 2 | No current directory group |
TAX — Taxation/Internal Revenue Code | 3 | 3 | taxes government spending |
TRD — Trade (domestic/foreign) | 4 | 4 | No current directory group |
Reviewed 2026-09-04.
Representative source language
Use canonical filings only; group exact source descriptions by reviewed issue code, sort codes and filings deterministically, select one description per code before selecting a second from any code, and preserve the source text exactly.
Issues related to FY27 health appropriations
Oppose IRA, PREP Act and vaccine liability.
Medicare and healthcare policy issues as they relate to drug pricing.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
General issues with tax reform and foreign tax issues.
Outside registrant context
Treat a registrant as outside-firm context only when the retained filing establishes the outside-registrant income reporting basis. Group the exact registrant name by reporting quarter without resolving firms beyond the reviewed filing identity.
| Registrant | 2026-Q1 | 2026-Q2 | Period total |
|---|---|---|---|
| MILLER STRATEGIES, LLC | 1 | 1 | 2 |
| THE DUBERSTEIN GROUP INC. | 1 | 1 | 2 |
| TODD STRATEGY GROUP | 1 | 1 | 2 |
These are registrant organizations named on retained filings, not individual lobbyists. A filing count does not measure effort, access, effectiveness, or policy result.
Retained filing records
Records are grouped by reporting quarter. Each disclosure opens with a keyboard-accessible summary and preserves its official code, description, amount states, and direct source.
2026-Q14 filings
PFIZER INC.1st Quarter (Jan 1 - Mar 31), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- Unreported
- Reported expenses
- $4,420,000
CPT — Copyright/Patent/Trademark
Intellectual Property Protections
Government entities listed: HOUSE OF REPRESENTATIVES
HCR — Health Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Government entities listed: Executive Office of the President (EOP), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
MMM — Medicare/Medicaid
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
Government entities listed: Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
TRD — Trade (domestic/foreign)
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Government entities listed: Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MILLER STRATEGIES, LLC1st Quarter (Jan 1 - Mar 31), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $150,000
- Reported expenses
- Unreported
MMM — Medicare/Medicaid
Medicare and healthcare policy issues as they relate to drug pricing.
Government entities listed: HOUSE OF REPRESENTATIVES, Treasury, Dept of
HCR — Health Issues
Oppose IRA, PREP Act and vaccine liability.
TAX — Taxation/Internal Revenue Code
General issues with tax reform and foreign tax issues.
LBR — Labor Issues/Antitrust/Workplace
Issues related to drug consolidation.
THE DUBERSTEIN GROUP INC.1st Quarter (Jan 1 - Mar 31), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $60,000
- Reported expenses
- Unreported
BUD — Budget/Appropriations
Issues related to FY27 health appropriations
Government entities listed: HOUSE OF REPRESENTATIVES, SENATE
HCR — Health Issues
Issues related to 340B Program Issues related to drug pricing
Government entities listed: HOUSE OF REPRESENTATIVES, White House Office
TODD STRATEGY GROUP1st Quarter (Jan 1 - Mar 31), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $60,000
- Reported expenses
- Unreported
PHA — Pharmacy
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
TAR — Tariff (miscellaneous tariff bills)
Issues related to tariff and trade policy. International Supply Chain.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
TRD — Trade (domestic/foreign)
Issues related to tariff and trade policy.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
2026-Q24 filings
THE DUBERSTEIN GROUP INC.2nd Quarter (Apr 1 - June 30), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $60,000
- Reported expenses
- Unreported
BUD — Budget/Appropriations
Issues related to FY27 health appropriations
Government entities listed: HOUSE OF REPRESENTATIVES, SENATE
HCR — Health Issues
Issues related to 340B Program Issues related to drug pricing
Government entities listed: HOUSE OF REPRESENTATIVES, White House Office
PFIZER INC.2nd Quarter (Apr 1 - June 30), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- Unreported
- Reported expenses
- $1,880,000
CPT — Copyright/Patent/Trademark
Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act
Government entities listed: SENATE
HCR — Health Issues
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Government entities listed: HOUSE OF REPRESENTATIVES, SENATE
MMM — Medicare/Medicaid
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Government entities listed: HOUSE OF REPRESENTATIVES, SENATE
TAX — Taxation/Internal Revenue Code
H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14
Government entities listed: HOUSE OF REPRESENTATIVES
TRD — Trade (domestic/foreign)
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Government entities listed: Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MILLER STRATEGIES, LLC2nd Quarter (Apr 1 - June 30), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $150,000
- Reported expenses
- Unreported
MMM — Medicare/Medicaid
Medicare and healthcare policy issues as they relate to drug pricing.
HCR — Health Issues
Issues related to 340B Program
Government entities listed: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
TAX — Taxation/Internal Revenue Code
General issues with tax reform and foreign tax issues.
LBR — Labor Issues/Antitrust/Workplace
Issues related to drug consolidation.
Government entities listed: Federal Trade Commission (FTC)
TODD STRATEGY GROUP2nd Quarter (Apr 1 - June 30), 2026
- Client name in filing
- PFIZER INC.
- Reported income
- $60,000
- Reported expenses
- Unreported
PHA — Pharmacy
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
TAR — Tariff (miscellaneous tariff bills)
Issues related to tariff and trade policy. International Supply Chain.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
TRD — Trade (domestic/foreign)
Issues related to tariff and trade policy.
Government entities listed: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Legislative record
Separate legislative context
No approved record in this collection
What was checked: Congress.gov records and the curated entity-link registry for this organization
What this means: No legislative context has passed review for this page. This does not mean no relevant legislation or filing references exist.
Political-finance record
Separate political-finance context
No approved record in this collection
What was checked: FEC committee records and the curated identity-link registry for this organization
What this means: No organization-linked committee aggregate has passed identity review for this page. This does not mean no committee relationship exists.
Federal award
Separate federal-award context
No approved record in this collection
What was checked: USAspending records and the curated recipient-identity link registry for this organization
What this means: No federal-award record has passed recipient-identity review for this page. This does not mean no award exists.
Reviewed links only
Why records are—or are not—shown together
Each category is checked separately. A missing approved link is an editorial state, not proof that no relationship exists.
No approved record in this collection
What was checked: The curated entity-link registry across lobbying, Congress.gov, FEC, and USAspending categories
What this means: No cross-source relationship has passed review for this organization in the current collection.
Interpretation
Limitations
- Source categories are presented separately and do not establish causation.
- The page includes only exact client names in the reviewed alias allowlist.
- Former-name evidence does not automatically merge subsidiaries, affiliates, committees, or separately named clients.
- LDA data was retrieved for Gov Influence analysis; the Senate Office of Public Records cannot vouch for data or analyses after retrieval.
- Gov Influence does not publish FEC individual-contributor records.
- These selected records cover Q1–Q2 2026, not a complete account of the organization’s activity.
- Timing, identity, and subject overlap do not establish causation, motive, access, effectiveness, wrongdoing, or legal conclusions.
- Names of individual lobbyists are not published on this profile.
Read the Methodology and Data Sources pages for the selection, evidence, and review rules used across the collection.
Continue exploring
Related reviewed records
issue
Healthcare, Prescription Drugs and Medicare
This page groups reviewed filings reported under Health Issues, Pharmacy, and Medicare/Medicaid codes. It shows disclosed activity without assigning support, opposition, motive, or policy impact.
issue
Taxes and Government Spending
Explore disclosed lobbying activity reported under federal Taxation/Internal Revenue Code and Budget/Appropriations issue codes. The grouping preserves each filing's original language and does not imply a position, policy outcome, or causal relationship.